Abstract 169P
Background
In the phase III IMbrave150 trial, atezo + bev demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) vs sorafenib (sor) in patients (pts) with unresectable HCC. Here we report on the AESIs for both atezo and bev in IMbrave150.
Methods
Eligible pts (N = 501) had unresectable HCC and were randomised 2:1 to receive atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w or sor 400 mg PO bid until unacceptable toxicity or loss of clinical benefit per investigator. Co-primary endpoints were OS and PFS by independent review facility–assessed RECIST 1.1. AESIs were defined by the sponsor and reported without judgement of causality. AESIs for atezo were based on the immune-mediated risks of atezo and other checkpoint inhibitors; AESIs for bev were based on known adverse drug reactions (ADRs) with bev. Analyses explored the incidence, nature and severity of AESIs as well as corticosteroid use.
Results
The safety-evaluable population included 329 pts in the atezo + bev arm and 156 pts in the sor arm. Median follow-up was 8.6 mo (data cutoff: 29 Aug 2019); median tx durations were 7.4 (atezo), 6.9 (bev) and 2.8 (sor) mo. AESIs for atezo occurred in 69% of pts receiving atezo + bev and also in 82% of pts receiving sor (Table). 12% of pts in the atezo + bev arm vs 3% of pts in the sor arm experienced AESIs requiring systemic corticosteroid tx within 30 days of AE onset. AESIs for bev occurred in 58% of pts receiving atezo + bev and 49% of pts receiving sor. The reported events were ADRs well known with bev, and their frequency and severity were consistent with the safety profile of bev and the underlying disease.
Conclusions
In IMbrave150, AESIs for atezo and bev were manageable. Further, the nature and severity of AESIs were consistent with the known safety profiles of the individual agents and the underlying disease Table: 169P
AESIs, n (%)a | Atezo + Bev n = 329 | Sor n = 156 | ||
All | G3-4 | All | G3-4 | |
For atezo | ||||
Pts with ≥ 1 | 226 (69) | 85 (26) | 128 (82) | 47 (30) |
Hepatic eventsb | 142 (43) | 70 (21) | 62 (40) | 26 (17) |
Inc AST | 64 (20) | 23 (7) | 26 (17) | 8 (5) |
Inc blood bilirubin | 43 (13) | 8 (2) | 22 (14) | 10 (6) |
Inc ALT | 46 (14) | 12 (4) | 14 (9) | 2 (1) |
Ascites | 23 (7) | 6 (2) | 9 (6) | 2 (1) |
Rash | 64 (20) | 2 (1) | 96 (62) | 21 (14) |
Hypothyroidism | 36 (11) | 0 | 4 (3) | 0 |
Infusion-related reactions | 36 (11) | 8 (2) | 0 | 0 |
For bev | ||||
Pts with ≥ 1 | 190 (58) | 76 (23) | 76 (49) | 29 (19) |
Hypertension | 102 (31) | 50 (15) | 40 (26) | 19 (12) |
Bleeding/haemorrhage | 83 (25) | 21 (6) | 27 (17) | 9 (6) |
Epistaxis | 34 (10) | 0 | 7 (5) | 1 (1) |
Upper GI bleedingc | 24 (7) | 15 (5) | 8 (5) | 8 (5) |
Proteinuria | 70 (21) | 10 (3) | 13 (8) | 1 (1) |
Inc, increased. a In ≥ 5% of pts. b ≥ 1 category possible. c Grouped MedDRA PT
.Clinical trial identification
NCT03434379.
Editorial acknowledgement
Medical writing assistance for this abstract was provided by Kia C. E. Walcott, PhD of Health Interactions, and funded by F. Hoffmann-La Roche, Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche, Ltd.
Funding
F. Hoffmann-La Roche, Ltd.
Disclosure
M. Kudo: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai; Honoraria (self): Bayer; Honoraria (self), Honoraria (institution): MSD; Honoraria (self), Honoraria (institution): BMS; Honoraria (self): Lilly; Honoraria (institution), Research grant/Funding (institution): EA Pharma; Research grant/Funding (institution): Gilead Sciences; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Sumitomo Dainippon Pharma; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Otsuka; Research grant/Funding (institution): AbbVie; Advisory/Consultancy: Ono; Advisory/Consultancy: Roche. M. Ikeda: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self): Taiho; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Chugai; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Research grant/Funding (institution): Yakult; Honoraria (self): Teijin; Honoraria (self), Advisory/Consultancy: Servier; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai; Honoraria (self), Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Ono; Research grant/Funding (institution): Bristol-Myers; Research grant/Funding (institution): MSD; Research grant/Funding (institution): J-Pharma; Research grant/Funding (institution): Aslan; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Astellas. A.X. Zhu: Advisory/Consultancy: Lilly; Advisory/Consultancy: Bayer; Advisory/Consultancy: Roche; Advisory/Consultancy: Merck; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Eisai. H.Y. Lim: Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: BMS; Advisory/Consultancy: Ono; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Roche. V. Breder: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy: Ipsen. P. Merle: Advisory/Consultancy, Ad Board: Bayer; Advisory/Consultancy, Ad Board: Eisai; Advisory/Consultancy, Ad Board: Exelixis; Advisory/Consultancy, Ad Board: Ipsen; Advisory/Consultancy, Ad Board: Lilly; Advisory/Consultancy, Ad Board: Roche; Advisory/Consultancy, Ad Board: AstraZeneca; Advisory/Consultancy, Ad Board: BMS; Advisory/Consultancy, Ad Board: MSD; Advisory/Consultancy, Ad Board: Merck; Advisory/Consultancy, Ad Board: Onxeo. A. Kaseb: Honoraria (self), Research grant/Funding (institution), Research Support: Genentech/Roche; Research grant/Funding (institution), Research Support: BMS; Research grant/Funding (institution), Research Support: Exelixis; Research grant/Funding (institution), Research Support: Bayer; Research grant/Funding (institution), Research Support: AdaptImmune; Research grant/Funding (institution), Research Support: Immatics; Research grant/Funding (institution), Research Support: Merck; Research grant/Funding (institution), Research Support: Eisai. D. Li: Advisory/Consultancy: Genentech. N. Ma: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. M. Villalobos: Full/Part-time employment: Genentech/Roche. S. Stanzel: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. V.E. Gaillard: Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche. D-Z. Xu: Full/Part-time employment: Roche. S. Hernandez: Shareholder/Stockholder/Stock options, Full/Part-time employment: Genentech/Roche. A-L. Cheng: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self): Yakuhin; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy: Genentech/Roche; Honoraria (self): Lilly; Advisory/Consultancy: Bayer Schering Pharma; Advisory/Consultancy: BeiGene, Ltd; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: CSR Pharma Group; Advisory/Consultancy: IQVIA; Advisory/Consultancy: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ono Pharmaceutical. R.S. Finn: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy: Exelixis; Advisory/Consultancy, Research grant/Funding (institution): Genentech/Roche; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Pfizer. P.R. Galle: Honoraria (self): Bayer; Speaker Bureau/Expert testimony: BMS; Honoraria (self): AstraZeneca; Honoraria (self): Lilly; Honoraria (self): Sirtex; Honoraria (self): MSD; Honoraria (self): Ipsen; Honoraria (self): Roche; Advisory/Consultancy: SillaJen; Advisory/Consultancy: Eisai. M. Ducreux: Full/Part-time employment: Sandoz (I); Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Serono; Honoraria (self): MSD Oncology; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self): Roche/Genentech; Honoraria (self), Advisory/Consultancy: Servier; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert testimony: Merck KGaA; Research grant/Funding (institution): Keocyt. All other authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session